Toxicity manifestations following intravenous Corynebacterium parvum administration to patients with ovarian and cervical carcinoma.
Manifestations of clinical toxicity were evaluated following 341 courses of intravenous Corynebacterium parvum adjuvant immunotherapy in patients with ovarian and cervical carcinoma. Most patients exhibited symptoms of minor toxicity, which decreased in intensity as subsequent courses of therapy were administered. Temperature elevations to 38.5 degrees C. were the most objectively measured signs of toxicity but temperature elevations greater than 38.5 degrees C. occurred following only 20.5 per cent of the infusions. Blood pressure alterations were not a serious problem and no serious central nervous system or renal toxicity was noted. The minor side effects should not preclude the use of C. parvum as an immunopotentiating agent if it is shown to be beneficial in the treatment of human malignant disease.
D001794:Blood Pressure; D001831:Body Temperature; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy; D004848:Epithelium / Q000276:immunology; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D007263:Infusions, Parenteral; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*; D011425:Propionibacterium acnes; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000628:therapy*